Lymphangitis carcinomatosa

Lymphangitis carcinomatosa is inflammation of the lymph vessels (lymphangitis) caused by a malignancy. Breast, lung, stomach, pancreas, and prostate cancers are the most common tumors that result in lymphangitis. Lymphangitis carcinomatosa was first described by pathologist Gabriel Andral in 1829 in a patient with uterine cancer.

Lymphangitis carcinomatosis most often affects people 40-49 years of age.[1]

Pathology

In most cases, lymphangitis carcinomatosis is caused by the dissemination of a tumor with its cells along the lymphatics.[2] However, in about 20 percent of cases, the inflammation of the lymphatic tubules (lymphangitis) is caused by a tumor that blocks the drainage of the lymph duct. In the lung, this is often caused by a centrally located mass, near the hilum of the lung that blocks lymphatic drainage.

Prognosis

Previously, the finding of lymphangitis carcinomatosis meant about a six month life expectancy.[2] However, improved treatment has improved survival in patients with lymphangitis carcinomatosis, with patients often surviving three or more years with treatment.[2]

History

Lymphangitis carcinomatosa was first described by pathologist Gabriel Andral in 1829 in a patient with uterine cancer.[3]

See also

References

  1. ↑ Bruce DM, Heys SD, Eremin O. (February 1996). "Lymphangitis carcinomatosa: a literature review.". J R Coll Surg Edinb. 41 (1): 7–13. PMID 8930034.
  2. 1 2 3 McKean, Sylvia; Jacobson, FL (2012). Principles and practice of hospital medicine: Chapter 108: Advanced Cardiothoracic Imaging. New York: McGraw-Hill. ISBN 9780071603898.
  3. ↑ Doyle L. (August 1989). "Gabriel Andral (1797-1876) and the first reports of lymphangitis carcinomatosa" (PDF). J R Soc Med. 82 (8): 491–3. PMC 1292257. PMID 2674433.
This article is issued from Wikipedia - version of the Monday, October 05, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.